Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032079145> ?p ?o ?g. }
- W3032079145 endingPage "13679" @default.
- W3032079145 startingPage "13670" @default.
- W3032079145 abstract "Acute myeloid leukemia (AML) is a deadly hematologic malignancy with poor prognosis, particularly in the elderly. Even among individuals with favorable-risk disease, approximately half will relapse with conventional therapy. In this clinical circumstance, the determinants of relapse are unclear, and there are no therapeutic interventions that can prevent recurrent disease. Mutations in the transcription factor CEBPA are associated with favorable risk in AML. However, mutations in the growth factor receptor CSF3R are commonly co-occurrent in CEBPA mutant AML and are associated with an increased risk of relapse. To develop therapeutic strategies for this disease subset, we performed medium-throughput drug screening on CEBPA/CSF3R mutant leukemia cells and identified sensitivity to inhibitors of lysine-specific demethylase 1 (LSD1). Treatment of CSF3R/CEBPA mutant leukemia cells with LSD1 inhibitors reactivates differentiation-associated enhancers driving immunophenotypic and morphologic differentiation. LSD1 inhibition is ineffective as monotherapy but demonstrates synergy with inhibitors of JAK/STAT signaling, doubling median survival in vivo. These results demonstrate that combined inhibition of JAK/STAT signaling and LSD1 is a promising therapeutic strategy for CEBPA/CSF3R mutant AML." @default.
- W3032079145 created "2020-06-05" @default.
- W3032079145 creator A5001288243 @default.
- W3032079145 creator A5008126484 @default.
- W3032079145 creator A5016492673 @default.
- W3032079145 creator A5029320446 @default.
- W3032079145 creator A5032381895 @default.
- W3032079145 creator A5033023115 @default.
- W3032079145 creator A5040589834 @default.
- W3032079145 creator A5060581274 @default.
- W3032079145 creator A5068010590 @default.
- W3032079145 creator A5073522080 @default.
- W3032079145 date "2020-05-29" @default.
- W3032079145 modified "2023-10-17" @default.
- W3032079145 title "Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia" @default.
- W3032079145 cites W1255676896 @default.
- W3032079145 cites W1977427229 @default.
- W3032079145 cites W1979594866 @default.
- W3032079145 cites W1989041292 @default.
- W3032079145 cites W1991543373 @default.
- W3032079145 cites W1999351948 @default.
- W3032079145 cites W2014677321 @default.
- W3032079145 cites W2019670746 @default.
- W3032079145 cites W2023014537 @default.
- W3032079145 cites W2032903538 @default.
- W3032079145 cites W203809443 @default.
- W3032079145 cites W2040928176 @default.
- W3032079145 cites W2083483484 @default.
- W3032079145 cites W2085917809 @default.
- W3032079145 cites W2100088478 @default.
- W3032079145 cites W2102331272 @default.
- W3032079145 cites W2102619694 @default.
- W3032079145 cites W2112364188 @default.
- W3032079145 cites W2113601375 @default.
- W3032079145 cites W2116858301 @default.
- W3032079145 cites W2116998791 @default.
- W3032079145 cites W2118270328 @default.
- W3032079145 cites W2124985265 @default.
- W3032079145 cites W2126283967 @default.
- W3032079145 cites W2128663764 @default.
- W3032079145 cites W2142047303 @default.
- W3032079145 cites W2148383862 @default.
- W3032079145 cites W2155046477 @default.
- W3032079145 cites W2169456326 @default.
- W3032079145 cites W2179438025 @default.
- W3032079145 cites W2233438852 @default.
- W3032079145 cites W2259755988 @default.
- W3032079145 cites W2313888337 @default.
- W3032079145 cites W2325939231 @default.
- W3032079145 cites W2341539131 @default.
- W3032079145 cites W2345356016 @default.
- W3032079145 cites W2346269859 @default.
- W3032079145 cites W2419140434 @default.
- W3032079145 cites W2503141921 @default.
- W3032079145 cites W2538288310 @default.
- W3032079145 cites W2544405043 @default.
- W3032079145 cites W2559537906 @default.
- W3032079145 cites W2586238242 @default.
- W3032079145 cites W2605336808 @default.
- W3032079145 cites W2768013244 @default.
- W3032079145 cites W2768521024 @default.
- W3032079145 cites W2786543241 @default.
- W3032079145 cites W2788202982 @default.
- W3032079145 cites W2788969237 @default.
- W3032079145 cites W2803237856 @default.
- W3032079145 cites W2808841066 @default.
- W3032079145 cites W2896480326 @default.
- W3032079145 cites W2900205062 @default.
- W3032079145 cites W2942951791 @default.
- W3032079145 cites W2943837693 @default.
- W3032079145 cites W2953419119 @default.
- W3032079145 cites W2990499535 @default.
- W3032079145 doi "https://doi.org/10.1073/pnas.1918307117" @default.
- W3032079145 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7306806" @default.
- W3032079145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32471953" @default.
- W3032079145 hasPublicationYear "2020" @default.
- W3032079145 type Work @default.
- W3032079145 sameAs 3032079145 @default.
- W3032079145 citedByCount "23" @default.
- W3032079145 countsByYear W30320791452020 @default.
- W3032079145 countsByYear W30320791452021 @default.
- W3032079145 countsByYear W30320791452022 @default.
- W3032079145 countsByYear W30320791452023 @default.
- W3032079145 crossrefType "journal-article" @default.
- W3032079145 hasAuthorship W3032079145A5001288243 @default.
- W3032079145 hasAuthorship W3032079145A5008126484 @default.
- W3032079145 hasAuthorship W3032079145A5016492673 @default.
- W3032079145 hasAuthorship W3032079145A5029320446 @default.
- W3032079145 hasAuthorship W3032079145A5032381895 @default.
- W3032079145 hasAuthorship W3032079145A5033023115 @default.
- W3032079145 hasAuthorship W3032079145A5040589834 @default.
- W3032079145 hasAuthorship W3032079145A5060581274 @default.
- W3032079145 hasAuthorship W3032079145A5068010590 @default.
- W3032079145 hasAuthorship W3032079145A5073522080 @default.
- W3032079145 hasBestOaLocation W30320791451 @default.
- W3032079145 hasConcept C104317684 @default.
- W3032079145 hasConcept C126322002 @default.
- W3032079145 hasConcept C203014093 @default.